Business Context and Reporting Period
This Form 8-K Current Report was filed by Vaxcyte, Inc. (PCVX) on June 27, 2024, with the earliest event reported on the same date. The filing addresses Item 5.02 regarding the appointment of a new director and associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to director compensation:
- Initial Equity Grant: Nonstatutory stock option valued at $800,000.
- Annual Equity Grant: Valued at $450,000 (75% stock options, 25% restricted stock units).
- Annual Cash Retainers: $50,000 for Board service and $7,500 for Compensation Committee service.
Material Changes
On June 27, 2024, the Board of Directors appointed John P. Furey as a Class II director, effective July 2, 2024. Mr. Furey was also appointed to the Compensation Committee. The Board determined that Mr. Furey qualifies as an independent director under Nasdaq Rules. There are no reported transactions between the Company and Mr. Furey requiring disclosure under Item 404(a) of Regulation S-K.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or discussion of risks and contingencies. The document focuses solely on the governance change and the terms of the Director Compensation Program, including vesting schedules (36 months for the initial grant; 12 months for annual grants) and change-in-control provisions.
Investor Verification Checklist
- Verify the current share price to calculate the number of shares underlying the $800,000 initial option grant and the $450,000 annual grants.
- Review the Company's 2020 Equity Incentive Plan for specific terms regarding option exercise prices and expiration.
- Confirm the total number of authorized shares remaining in the equity plan to assess dilution impact.
- Check subsequent filings for the actual grant date and exercise price of the initial award.